目的 探討康艾注射液聯(lián)合西妥昔單抗治療晚期結(jié)直腸癌的臨床療效。方法 選取2016年1月-2017年1月于青島市商業(yè)職工醫(yī)院進(jìn)行治療的晚期結(jié)直腸癌患者76例，根據(jù)治療方案的差別分為對(duì)照組（38例）和治療組（38例）。對(duì)照組患者靜脈滴注西妥昔單抗注射液，初始劑量為400 mg/（m²·周），滴速≤ 5 mL/min，滴注時(shí)間120 min，然后維持250 mg/（m²·周）。治療組在對(duì)照組的基礎(chǔ)上靜脈滴注康艾注射液，40 mL加入5%葡萄糖注射液250 mL，1次/d。兩組患者均治療6周。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者生存質(zhì)量改善情況、血清學(xué)指標(biāo)和不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組的客觀緩解率（ORR）和臨床獲益率（CBR）分別為28.95%%、52.63%，均分別顯著低于治療組的50.00%、73.68%，兩組比較差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組改善率為68.42%，顯著低于治療組的92.11%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清血管內(nèi)皮生長(zhǎng)因子（VEGF）、缺氧誘導(dǎo)因子-1α（HIF-1α）和基質(zhì)金屬蛋白酶-9（MMP-9）水平明顯降低，而IL-2和干擾素-γ（IFN-γ）水平明顯增高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述指標(biāo)改善情況明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 康艾注射液聯(lián)合西妥昔單抗可有效提高晚期結(jié)直腸癌患者機(jī)體免疫功能，并可顯著改善患者生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Kang'ai Injection combined with cetuximab in treatment of advanced colorectal cancer. Methods Patients (76 cases) with advanced colorectal cancer in Qingdao Commercial Staff Hospital from January 2016 to January 2017 were divided into control (38 cases) and treatment (38 cases) groups based on different treatments. Patients in the control group were iv administered with Cetuximab Solution for infusion, the initial dosage was 400 mg/(m²·week), the speed ≤ 5 mL/min, and the drip time was 120 min, then maintained the speed at 250 mg/(m²·week). Patients in the treatment group were iv administered with Kang'ai Injection on the basis of the control group, 40 mL added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of life quality, serological indexes and adverse reactions in two groups before and after treatment were compared. Results After treatment, ORR and CBR in the control group were 28.95%% and 52.63%, which were significantly lower than 50.00% and 73.68% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the improvement rate in the control group was 68.42%, which was significantly lower than 92.11% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the VEGF, HIF-1α and MMP-9 levels in two groups were significantly decreased, but IL-2 and IFN-γ levels were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the improvement of these indexes in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Kang'ai Injection combined with cetuximab can improve the immunity in treatment of advanced colorectal cancer, and can effectively improve the quality of life, which has a certain clinical application value.